Cargando…
Guidance on take-home naloxone distribution and use by community overdose responders in Canada
BACKGROUND: The increasing toxicity of opioids in the unregulated drug market has led to escalating numbers of overdoses in Canada and worldwide; takehome naloxone (THN) is an evidence-based intervention that distributes kits containing naloxone to people in the community who may witness an overdose...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462409/ https://www.ncbi.nlm.nih.gov/pubmed/37640401 http://dx.doi.org/10.1503/cmaj.230128 |
_version_ | 1785098024753561600 |
---|---|
author | Ferguson, Max Rittenbach, Katherine Leece, Pamela Adams, Alison Ali, Farihah Elton-Marshall, Tara Burmeister, Charlene Brothers, Thomas D. Medley, Andrea Choisil, Paul Strike, Carol Ng, Justin Lorenzetti, Diane L. Gallant, Kat Buxton, Jane A. |
author_facet | Ferguson, Max Rittenbach, Katherine Leece, Pamela Adams, Alison Ali, Farihah Elton-Marshall, Tara Burmeister, Charlene Brothers, Thomas D. Medley, Andrea Choisil, Paul Strike, Carol Ng, Justin Lorenzetti, Diane L. Gallant, Kat Buxton, Jane A. |
author_sort | Ferguson, Max |
collection | PubMed |
description | BACKGROUND: The increasing toxicity of opioids in the unregulated drug market has led to escalating numbers of overdoses in Canada and worldwide; takehome naloxone (THN) is an evidence-based intervention that distributes kits containing naloxone to people in the community who may witness an overdose. The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal THN programs, using evidence from scientific and grey literature and community evidence that reflects 11 years of THN distribution in Canada. METHODS: The Naloxone Guidance Development Group — a multidisciplinary team including people with lived and living experience and expertise of drug use — used the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument to inform development of this guidance. We considered published evidence identified through systematic reviews of all literature types, along with community evidence and expertise, to generate recommendations between December 2021 and September 2022. We solicited feedback on preliminary recommendations through an External Review Committee and a public input process. The project was funded by the Canadian Institutes of Health Research through the Canadian Research Initiative in Substance Misuse. We used the Guideline International Network principles for managing competing interests. RECOMMENDATIONS: Existing evidence from the literature on THN was of low quality. We incorporated evidence from scientific and grey literature, and community expertise to develop our recommendations. These were in 3 areas: routes of naloxone administration, THN kit contents and overdose response. Take-home naloxone programs should offer the choice of both intramuscular and intranasal formulations of naloxone in THN kits. Recommended kit contents include naloxone, a naloxone delivery device, personal protective equipment, instructions and a carrying case. Trained community overdose responders should prioritize rescue breathing in the case of respiratory depression, and conventional cardiopulmonary resuscitation in the case of cardiac arrest, among other interventions. INTERPRETATION: This guidance development project provides direction for THN programs in Canada in the context of limited published evidence, with recommendations developed in collaboration with diverse stakeholders. |
format | Online Article Text |
id | pubmed-10462409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | CMA Impact Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104624092023-08-29 Guidance on take-home naloxone distribution and use by community overdose responders in Canada Ferguson, Max Rittenbach, Katherine Leece, Pamela Adams, Alison Ali, Farihah Elton-Marshall, Tara Burmeister, Charlene Brothers, Thomas D. Medley, Andrea Choisil, Paul Strike, Carol Ng, Justin Lorenzetti, Diane L. Gallant, Kat Buxton, Jane A. CMAJ Guideline BACKGROUND: The increasing toxicity of opioids in the unregulated drug market has led to escalating numbers of overdoses in Canada and worldwide; takehome naloxone (THN) is an evidence-based intervention that distributes kits containing naloxone to people in the community who may witness an overdose. The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal THN programs, using evidence from scientific and grey literature and community evidence that reflects 11 years of THN distribution in Canada. METHODS: The Naloxone Guidance Development Group — a multidisciplinary team including people with lived and living experience and expertise of drug use — used the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument to inform development of this guidance. We considered published evidence identified through systematic reviews of all literature types, along with community evidence and expertise, to generate recommendations between December 2021 and September 2022. We solicited feedback on preliminary recommendations through an External Review Committee and a public input process. The project was funded by the Canadian Institutes of Health Research through the Canadian Research Initiative in Substance Misuse. We used the Guideline International Network principles for managing competing interests. RECOMMENDATIONS: Existing evidence from the literature on THN was of low quality. We incorporated evidence from scientific and grey literature, and community expertise to develop our recommendations. These were in 3 areas: routes of naloxone administration, THN kit contents and overdose response. Take-home naloxone programs should offer the choice of both intramuscular and intranasal formulations of naloxone in THN kits. Recommended kit contents include naloxone, a naloxone delivery device, personal protective equipment, instructions and a carrying case. Trained community overdose responders should prioritize rescue breathing in the case of respiratory depression, and conventional cardiopulmonary resuscitation in the case of cardiac arrest, among other interventions. INTERPRETATION: This guidance development project provides direction for THN programs in Canada in the context of limited published evidence, with recommendations developed in collaboration with diverse stakeholders. CMA Impact Inc. 2023-08-28 2023-08-28 /pmc/articles/PMC10462409/ /pubmed/37640401 http://dx.doi.org/10.1503/cmaj.230128 Text en © 2023 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Guideline Ferguson, Max Rittenbach, Katherine Leece, Pamela Adams, Alison Ali, Farihah Elton-Marshall, Tara Burmeister, Charlene Brothers, Thomas D. Medley, Andrea Choisil, Paul Strike, Carol Ng, Justin Lorenzetti, Diane L. Gallant, Kat Buxton, Jane A. Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title | Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title_full | Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title_fullStr | Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title_full_unstemmed | Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title_short | Guidance on take-home naloxone distribution and use by community overdose responders in Canada |
title_sort | guidance on take-home naloxone distribution and use by community overdose responders in canada |
topic | Guideline |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462409/ https://www.ncbi.nlm.nih.gov/pubmed/37640401 http://dx.doi.org/10.1503/cmaj.230128 |
work_keys_str_mv | AT fergusonmax guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT rittenbachkatherine guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT leecepamela guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT adamsalison guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT alifarihah guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT eltonmarshalltara guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT burmeistercharlene guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT brothersthomasd guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT medleyandrea guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT choisilpaul guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT strikecarol guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT ngjustin guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT lorenzettidianel guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT gallantkat guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada AT buxtonjanea guidanceontakehomenaloxonedistributionandusebycommunityoverdoserespondersincanada |